TARS vs UTHR
Tarsus Pharmaceuticals, Inc. vs United Therapeutics — AI-powered side-by-side comparison
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
VS
UTHR
United Therapeutics
72
Buy
| Metric | TARS | UTHR |
|---|
| AI Score |
63
|
72
|
| Price |
$69.50
|
$514.89
|
| P/E Ratio |
-63.72×
|
17.05×
|
| ROE |
-19.3%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
90.6%
|
86.1%
|
| Debt / Equity |
0.26×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
80.7
|
52.2
|
| Beta |
0.512
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for TARS versus UTHR.
UTHR leads by 9 points.
UTHR scores 72/100 (Buy) versus TARS at 63/100 (Buy).
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.